International medical imaging IT company Sectra (STO: SECT B) has announced that its digital pathology solution now has an interface with Finalist LIMS (Laboratory Information Management System). The interface facilitates a more efficient, completely paper-free pathology review workflow in which pathologists have access to both digital images and patient information from one single work location. This enables reduced lead times, thereby increasing efficiency in cancer care.
The interface between Sectra’s digital pathology solution and Finalist’s LIMS also improves the process of scanning glass slides. The appropriate scanning protocol is automatically selected, enabling high-volume scanning without any manual interference.
“This interface is key for the Dutch market and the latest example of our consistent strategy to improve reading and reporting efficiency in pathology through tight integration with surrounding IT systems, such as different LIMS systems,” says Simon Häger, Product Manager for Sectra’s pathology solution.
About Sectra’s digital pathology solution
Sectra provides a complete solution for primary diagnostics in pathology. The solution includes archiving and storage solutions together with high-end review workstations. It allows pathologists to make their diagnoses and reports with higher precision and less time spent per case. Sectra’s solution for digital pathology is built on the same platform as Sectra’s radiology PACS, the solution for managing radiology images. With a shared technical platform, images from both of the diagnostic specialties can be stored and displayed in a single system. This enables deeper cooperation between radiologists and pathologists and facilitates, for example, multidisciplinary rounds, which is a step in integrated diagnostics.
European and Scandinavian pathology departments are in the process of digitizing their work, but nonetheless, only a few hospitals have implemented full-scale digital pathology solutions. In the US, digital pathology for primary diagnostics is still pending FDA approval.
Source & Image Credit : Sectra